Title: A Novel Melanoma Vaccination TherapyPrincipal Investigator: Joel Glasgow, Ph.D.Department: Gene TherapyFunding Period: 8/07-7/09Brief Description: A system for the in vivo activation of DCs that employs a fusion protein comprised of aTAA fused to the DC-relevant CD40 ligand (CD40L) has shown promise for inducing anti-tumor immuneresponse. In this system, the fusion protein (TAA-CD40L) is secreted from normal skin cells followingtransduction with an adenovirus type 5 (Ad5) vector encoding the fusion. DCs in the skin then take up thisfusion protein and elicit a TAA-specific anti-tumor response via cytotoxic T-cells.While this fusion protein: strategy has significant potential to realize the benefits afforded by DC-based immunotherapy, significantvector-associated limitations must be addressed prior to clinical translation. The purpose of this study was toproduce modifications to the vector that would increase is immunizing potential. A major attraction of thisapplication is the use of topical adenovirus vectors that target cutaneous dendritic cells.Extramural Funding: Too early to assessPublications:Perreau M, Mennechet F, Serratrice N, Glasgow JN, Curiel DT, Wodrich H and Kremer EJ. Contrasting effectsof human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of humandendritic cells: implications for clinical efficacy. / Virol 81(7):3272-84, 2007.
Showing the most recent 10 out of 228 publications
